Antibacterial Agents TRIZ Cases

Formula I oxazolidinone compounds kill or inhibit microbial growth through modular R1 substituent design.

Antibody half molecules remain separate in plasma and form heterodimers only on target cells, reducing off-target side effects.

Modified hydrazide derivatives overcome antimicrobial resistance by combining aromatic rings to treat infections caused by resistant strains.

Covalent modification of mutant EGFR overcomes T790M resistance in non-small cell lung cancer while maintaining selectivity across multiple kinase families.

Crystalline form B of the NXL104 sodium salt resolves instability and hygroscopicity issues in amorphous materials.

A liquid antibacterial composition incorporates trichlorocarbanilide with lower glycols to maintain visual clarity and stability.

Multi-epitope fusion antigen proteins combine conserved Shigella virulence determinants to induce robust cross-protective IgG responses.

Merging Ogawa and Inaba antigens into one strain simplifies vaccine production while maintaining broad protection against cholera and ETEC.

Modifying elvitegravir and cobicistat doses overcomes rifabutin-induced metabolic suppression, sustaining antiviral efficacy.

A polynucleotide delivery method downregulates bacterial resistance pathways to restore antibiotic susceptibility in treated cells.

A vaginal composition uses 2-phenylethanol, propionic acid, and benzoic acid to inhibit pathogens while promoting Lactobacilli growth.

Novel tetrasubstituted benzimidazolium compounds with high topological polar surface area sustain epithelial sodium channel blockade.

Engineered Gram-negative bacteria lacking lipopolysaccharide resolve the trade-off between therapeutic efficacy and septic shock risk.

Imidazole-pyrazole derivatives treat Acinetobacter baumannii infections by overcoming carbapenem resistance mechanisms to reduce mortality.

In vitro assembly of purified T4 capsid proteins with Hoc and Soc antigens resolves unpredictable in vivo variability, enabling reproducible vaccine platforms.

Coumarin-chalcone compounds disrupt biofilms by downregulating quorum sensing, enhancing antibiotic susceptibility to treat resistant infections.

Macrocyclic urea and sulfamide derivatives inhibit TAFIa to promote endogenous fibrinolysis without increasing bleeding risk.

Pancreatic enzyme inhibitors accelerate tissue regeneration and angiogenesis through targeted proteolytic activity attenuation.

Replacing high alcohol concentrations with an iodine and sugar complex reduces irritation to sensitive mucosal tissues while maintaining rapid bacterial kill.

Synthesizing the imidazole compound with high yields via solvent-free cyclocondensation resolves synthesis difficulty and simplifies purification.

Nigella sativa seed oil compositions inactivate the EHP polar tube extrusion mechanism to resolve economic losses from uncontrolled shrimp infections.

Non-coding RNA biomarkers enable rapid microbial detection through sequence-specific molecular recognition.

Isoprenyl compounds decolonize bacteria on epithelial tissue, addressing antibiotic resistance in wound antisepsis.

Specific weight ratios of quercetin with vitamins B3, B6, B12, C, and E extend half-life to treat mental fatigue and viral infections.

Maternal administration of non-replicating Lactobacillus paracasei CBA L74 boosts infant immune strength against pathogens.

PIV5 vectors insert heterologous sequences between HN and L genes to bypass egg-based production delays and enable rapid strain adaptation.

A symmetric polypeptide with hydrophobic and charged regions targets Fusobacterium nucleatum membranes.

Formula I pyrimidyl cyclopentanes inhibit AKT protein kinases, addressing the lack of effective inhibitors for hyperproliferative diseases.

Pairing family I and III fHbp antigens broadens strain coverage against serogroup B meningococcus, resolving poor protection from single-sequence vaccines.

Novel indolizine dicarboxylate derivatives overcome multidrug resistance in Mycobacterium tuberculosis through targeted molecular design.

Sialic acid binding molecules dampen pro-inflammatory cytokine cascades without releasing harmful bacterial components, resolving antibiotic-induced toxicity.

Segmented 1-substituted benzoyl pyrroloquinoline derivatives overcome multidrug resistance in Mycobacterium tuberculosis.

Halogenated desosamine sugars enhance ribosomal binding affinity in macrolide antibiotics.

Selective bacterial glutaminyl cyclase inhibitors target periodontal pathogens, reducing resistance development and preserving the natural oral microbiome.

Replacing sodium chloride with sorbitol prevents antigen precipitation at low ionic strength, preserving immunogenicity.

Novel picolinamide compounds selectively inhibit 11β-HSD1 to treat metabolic syndromes without causing hypokalemia or hypertension.

Small molecule 2-cyclopenten-1-one oxime derivatives replace injectable biologics to inhibit TNF-alpha and reduce treatment costs.

Segmented dipeptide epoxy ketone compounds target LMP2 subunits to resolve inadequate specificity in current proteasome inhibition strategies.

Thujopsene-based compositions treat infections by inhibiting viral replication and microbial growth, addressing side effects from conventional antibiotics.

Uridine and pyruvate compounds buffer mitochondrial interference from antibiotics, eliminating adverse side effects while maintaining therapeutic efficacy.

Segmented enterically-coated lyospheres resolve chemical instability and poor powder flow by isolating macromolecules in robust, individually coated units.

Buffered near-neutral composition with moderate osmolarity removes biofilms from ciliated tissues while preventing irreversible deciliation.

Arenicin polypeptides disrupt bacterial membranes to restore treatment effectiveness against multiple drug-resistant E. coli strains.

Peptides disrupt the PAK-PIX-GIT-MEK complex to reduce tissue injury from acute lung injury and stroke.

Homoleptic metal coordination complexes induce apoptosis in fungal cells.

Formula I compounds inhibit glyoxalase enzymes, disrupting bacterial metabolism to treat infections resistant to conventional antibiotics.